Tyler Groves1, Paul Robinson2, Veronica Wiley3, Dominic A Fitzgerald2. 1. Sydney Medical School, University of Sydney, New South Wales, Australia; Department of Respiratory Medicine, The Children's Hospital at Westmead, New South Wales, Australia. Electronic address: tgro4924@uni.sydney.edu.au. 2. Department of Respiratory Medicine, The Children's Hospital at Westmead, New South Wales, Australia; Discipline of Pediatrics and Child Health, Sydney Medical School, University of Sydney, New South Wales, Australia. 3. Discipline of Pediatrics and Child Health, Sydney Medical School, University of Sydney, New South Wales, Australia; New South Wales Newborn Screening Program, The Children's Hospital at Westmead, New South Wales, Australia.
Abstract
OBJECTIVE: To describe the clinical course of children who have intermediate sweat chloride values on initial screening for cystic fibrosis (CF). STUDY DESIGN: We performed a retrospective review of children with intermediate sweat chloride values (raised immunoreactive trypsinogen/1 copy of p.F508del CF mutation on newborn screening (NBS)/sweat chloride value of 30-59 mmol/L) presenting to The Children's Hospital at Westmead over 15 years. Patients with an intermediate sweat chloride evolving to a formal diagnosis of CF (termed "delayed CF") were matched (2:1) with NBS positive patients with CF (termed "NBS positive CF"). Clinical outcomes were compared. RESULTS: Fourteen of 29 (48%, 95% CI 0.3-0.66) patients with intermediate sweat chloride value evolved to a diagnosis of CF and were matched with 28 NBS positive patients with CF. Delayed CF had less pancreatic insufficiency (OR 0.06, 95% CI 0.01-0.44, P = .006), less colonization with nonmucoid Pseudomonas aeruginosa (OR 0.04, 95% CI 0.01-0.38, P = .005), milder obstructive lung disease (forced expiratory volume in 1 second/forced vital capacity ratio), and overall disease severity (Shwachman scores) at 10 years (mean difference 5.93, 95% CI 0.39-11.46, P = .04; mean difference 4.72, 95% CI 0.9-8.53, P = .015, respectively). Nutritional outcomes were better at 2 years for delayed CF but did not persist to later ages. CONCLUSIONS: In this cohort, approximately one-half of infants with intermediate sweat chloride value were later diagnosed with CF. The clinical course of delayed CF was milder in some aspects compared with NBS positive CF. These results emphasize the importance of ongoing follow-up of infants with intermediate sweat chloride values. Crown
OBJECTIVE: To describe the clinical course of children who have intermediate sweat chloride values on initial screening for cystic fibrosis (CF). STUDY DESIGN: We performed a retrospective review of children with intermediate sweat chloride values (raised immunoreactive trypsinogen/1 copy of p.F508del CF mutation on newborn screening (NBS)/sweat chloride value of 30-59 mmol/L) presenting to The Children's Hospital at Westmead over 15 years. Patients with an intermediate sweat chloride evolving to a formal diagnosis of CF (termed "delayed CF") were matched (2:1) with NBS positive patients with CF (termed "NBS positive CF"). Clinical outcomes were compared. RESULTS: Fourteen of 29 (48%, 95% CI 0.3-0.66) patients with intermediate sweat chloride value evolved to a diagnosis of CF and were matched with 28 NBS positive patients with CF. Delayed CF had less pancreatic insufficiency (OR 0.06, 95% CI 0.01-0.44, P = .006), less colonization with nonmucoid Pseudomonas aeruginosa (OR 0.04, 95% CI 0.01-0.38, P = .005), milder obstructive lung disease (forced expiratory volume in 1 second/forced vital capacity ratio), and overall disease severity (Shwachman scores) at 10 years (mean difference 5.93, 95% CI 0.39-11.46, P = .04; mean difference 4.72, 95% CI 0.9-8.53, P = .015, respectively). Nutritional outcomes were better at 2 years for delayed CF but did not persist to later ages. CONCLUSIONS: In this cohort, approximately one-half of infants with intermediate sweat chloride value were later diagnosed with CF. The clinical course of delayed CF was milder in some aspects compared with NBS positive CF. These results emphasize the importance of ongoing follow-up of infants with intermediate sweat chloride values. Crown
Authors: Debra Boyer; Mary Nevin; Carey C Thomson; Don B Sanders; Stamatia Alexiou; Samuel B Goldfarb; Jennifer L Nicholas; Paul G Thacker; Andrea M Coverstone; Albert Faro; George Cheng; Adnan Majid; Paul E Moore Journal: Ann Am Thorac Soc Date: 2015-11
Authors: H Levy; M Nugent; K Schneck; D Stachiw-Hietpas; A Laxova; O Lakser; M Rock; M K Dahmer; J Biller; S Z Nasr; M Baker; S A McColley; P Simpson; P M Farrell Journal: Clin Genet Date: 2016-01-20 Impact factor: 4.438
Authors: Alethéa Guimarães Faria; Fernando Augusto Lima Marson; Carla Cristina Souza Gomez; Maria de Fátima Servidoni; Antônio Fernando Ribeiro; José Dirceu Ribeiro Journal: Front Pediatr Date: 2017-10-26 Impact factor: 3.418
Authors: Alethéa Guimarães Faria; Fernando Augusto Lima Marson; Carla Cristina de Souza Gomez; Maria Ângela Gonçalves de Oliveira Ribeiro; Lucas Brioschi Morais; Maria de Fátima Servidoni; Carmen Sílvia Bertuzzo; Eulália Sakano; Maura Goto; Ilma Aparecida Paschoal; Mônica Corso Pereira; Gabriel Hessel; Carlos Emílio Levy; Adyléia Aparecida Dalbo Contrera Toro; Andressa Oliveira Peixoto; Maria Cristina Ribeiro Simões; Elizete Aparecida Lomazi; Roberto José Negrão Nogueira; Antônio Fernando Ribeiro; José Dirceu Ribeiro Journal: Diagn Pathol Date: 2016-10-26 Impact factor: 2.644